Neurizon unveils preclinical protein clearance data

Neurizon Therapeutics (ASX:NUZ) has unveiled compelling new preclinical data regarding its lead compound, NUZ-001, demonstrating an advancement in the fight against neurodegenerative diseases like Amyotrophic Lateral Sclerosis.

The findings characterise a unique biological mechanism of action wherein NUZ-001 and its sulfone metabolite actively enhance multiple protein clearance pathways within neuronal systems.

The accumulation of aggregated proteins often overwhelms a cell’s natural defences, leading to dysfunction and eventual cell death.

Neurizon’s research confirms that NUZ-001 addresses this by boosting activity in two vital, complementary systems: autophagy and the ubiquitin-proteasome system.

While autophagy handles the bulk degradation of damaged protein clusters, the proteasome selectively removes smaller aggregates.

Together, the dual-action approach aims to restore cellular homeostasis more effectively than traditional therapies that target only a single pathway.

The study utilised physiologically relevant human cellular models to measure specific markers of protein clearance.

Researchers observed marked reductions in p62 and LC3 proteins—industry-standard indicators of autophagic flux—following treatment with NUZ-001.

The results suggest a more efficient degradation of toxic protein build-up, strengthening the scientific foundation for the compound as it progresses through clinical evaluation.